Senzime Publishes Annual and Sustainability Report for 2025
Rhea-AI Summary
Senzime (OTCQX:SNZZF / STO:SEZI) published its 2025 annual and sustainability report on April 24, 2026, available on the company website.
The company reports it exceeded SEK 100 million in sales, increased growth rate, met its sales growth targets in constant currencies, kept costs according to plan, secured several strategic wins, and says it laid the foundation for profitability in 2026.
Positive
- Sales exceeded SEK 100 million in 2025
- Sales growth targets met in constant currencies
- Costs kept according to plan, supporting margin control
- Several major strategic wins that strengthened market position
Negative
- None.
AI-generated analysis. How Rhea-AI works. Not financial advice.
UPPSALA, SE / ACCESS Newswire / April 24, 2026 / Senzime (STO:SEZI)(OTCQX:SNZZF) - Senzime AB (publ) announces today that the company's annual and sustainability report for 2025 is published and available on www.senzime.com
"2025 was the year we increased the growth rate and exceeded SEK 100 million in sales. We achieved our communicated goals for sales growth in constant currencies and kept costs according to plan. We secured several major strategic wins, strengthened our leading market position, and laid the foundation for profitability in 2026", commented Philip Siberg, CEO of Senzime
For further information, please contact:
Philip Siberg, CEO of Senzime AB
Phone: +46 (0) 707 90 67 34, e-mail: philip.siberg@senzime.com
Slavoljub Grujicic, CFO
Phone: +46 (0) 76 306 60 11, e-mail: slavoljub.grujicic@senzime.com
About Senzime
Senzime is a leading medical device company at the forefront of a changing healthcare market, driven by new clinical guidelines and emerging technologies. Established in 1999, Senzime develops and markets precision-based monitoring systems that improve outcomes, reduce costs, and advance perioperative patient safety. The flagship solution is the TetraGraph® system, proven best-in-class for accurate monitoring of neuromuscular transmission during surgery and used in thousands of operating rooms across the globe. The system helps to secure precise dosing of paralytic drugs and provides enhanced insights to safeguard every patient's journey, from anesthesia to recovery.
Headquartered in Uppsala, Sweden, Senzime is publicly traded on the Nasdaq Stockholm Main Market (SEZI), with cross-trading on the US OTCQX Market (SNZZF), and backed by long-term investors. More information is available at senzime.com.
This information is information that Senzime is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 2026-04-24 12:00 CEST.
Attachments
SOURCE: Senzime
View the original press release on ACCESS Newswire